Spark Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

Spark Investment Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,380	Closed	-$10K	–	874
2016 Q4	$10K	Sell	2,380 -3,730	-61%	-$16.7K	﹤0.01%	763
2016 Q3	$34K	Sell	6,110 -1,210	-17%	-$7.55K	﹤0.01%	800
2016 Q2	$46K	Sell	7,320 -3,643	-33%	-$29.1K	﹤0.01%	755
2016 Q1	$92K	Sell	10,963 -11,997	-52%	-$103K	0.01%	704
2015 Q4	$234K	Buy	22,960 +19,933	+659%	+$203K	0.03%	553
2015 Q3	$35K	Buy	3,027 +1,407	+87%	+$22.4K	﹤0.01%	656
2015 Q2	$31K	Hold	1,620	–	–	﹤0.01%	642
2015 Q1	$28K	Sell	1,620 -6,420	-80%	-$126K	﹤0.01%	693
2014 Q4	$147K	Sell	8,040 -1,350	-14%	-$29K	0.02%	540
2014 Q3	$227K	Buy	9,390 +4,750	+102%	+$137K	0.03%	494
2014 Q2	$169K	Buy	+4,640	New	+$187K	0.03%	511

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Spark Investment Management's PLX Position: Q1 2017 in Review

Spark Investment Management sold out of Protalix BioTherapeutics (PLX) in Q1 2017, closing a stake of 2,380 shares — an estimated $10K sold.

Spark Investment Management first reported a position in PLX in Q2 2014 and held it in 11 quarters. The position peaked at $234K in Q4 2015. 28 funds tracked by Wall St. Rank hold PLX as of Q1 2017.

Spark Investment Management reported no remaining Protalix BioTherapeutics position as of Q1 2017 after selling out during the quarter.
Spark Investment Management sold 2,380 Protalix BioTherapeutics shares in Q1 2017, an estimated $10K.
Spark Investment Management first reported a position in Protalix BioTherapeutics in Q2 2014 and held it in 11 quarters.
Spark Investment Management's Protalix BioTherapeutics position peaked at $234K in Q4 2015.
28 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2017.

Based on Spark Investment Management's 13F filing for Q1 2017, filed 11 May 2017.